Search company, investor...

Avidimer Therpeutics


Other Investors | Alive

About Avidimer Therpeutics

Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases

Headquarters Location

P.O. Box 7735

Ann Arbor, Michigan, 48107,

United States

Missing: Avidimer Therpeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Avidimer Therpeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Avidimer Therpeutics Frequently Asked Questions (FAQ)

  • Where is Avidimer Therpeutics's headquarters?

    Avidimer Therpeutics's headquarters is located at P.O. Box 7735, Ann Arbor.

  • What is Avidimer Therpeutics's latest funding round?

    Avidimer Therpeutics's latest funding round is Other Investors.

  • Who are the investors of Avidimer Therpeutics?

    Investors of Avidimer Therpeutics include Flagship Pioneering.

  • Who are Avidimer Therpeutics's competitors?

    Competitors of Avidimer Therpeutics include Phico Therapeutics, Momenta Pharmaceuticals, Aquinox Pharmaceuticals, Igenica Biotherapeutics, Anacor Pharmaceuticals and 13 more.

Compare Avidimer Therpeutics to Competitors


is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.


Neomics is a drug discovery and diagnostics company with a unique cancer target and biomarker discovery platform. In particular, Neomics is focused on novel targets and biomarkers relevant to aminoacyl RNA synthetases (ARS). They have preclinical and clinical validation of their targets and biomarkers.

NovaDigm Therapeutics

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.


Sopherion is a therapeutics platform company initially focused on cancer.

Phico Therapeutics Logo
Phico Therapeutics

Phico Therapeutics is developing SASPject PT3.8, an antibacterial therapy for the systemic treatment of patients with serious Pseudomonas aeruginosa (P. aeruginosa) infections, which have a high mortality rate.

Sequoia Pharmaceuticals

Sequoia Pharmaceuticals, Inc. is engaged in the discovery and development of antiviral therapeutics, with a focus on developing new treatments for drug-resistant infectious diseases such as HIV/AIDS and HCV-induced hepatitis. Sequoia Pharmaceuticals is located in Gaithersburg, Md.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.